Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 22, 2017
Pharmacy Choice - Pharmaceutical News - Tokai Pharmaceuticals Posts Preclinical Results from the University of Maryland Showing Galeterone and Analogs Inhibit Pancreatic Cancer Cell Growth [Manufacturing Close - Up] - October 22, 2017

Pharmacy News Article

 4/23/15 - Tokai Pharmaceuticals Posts Preclinical Results from the University of Maryland Showing Galeterone and Analogs Inhibit Pancreatic Cancer Cell Growth [Manufacturing Close - Up]

Tokai Pharmaceuticals reported that scientists in the laboratory of Vincent Njar, PhD, at the University of Maryland School of Medicine presented preclinical data showing that galeterone and novel analogs of galeterone inhibited growth, survival and migration of human pancreatic ductal adenocarcinoma (PDAC) cells.

In a release, the Company noted that these data were presented in a poster presentation titled, "Galeterone and Its Novel Analogs Induce Profound Anti-Cancer Activities in Human Pancreatic Cancer Cell Lines," abstract number 1764, at the 2015 American Association for Cancer Research (AACR) in Philadelphia, Pennsylvania.

"We are excited to see the activity of galeterone and its novel analogs in pancreatic cancer cells," stated Jodie Morrison, President and Chief Executive Officer of Tokai Pharmaceuticals. "Based on these data we believe galeterone and its novel analogs may have activity in this tumor type where there is a significant need for new therapies. These preclinical results also support the potential of galeterone beyond its lead indication in prostate cancer and further demonstrate the potential of the ARDA platform."

Tokai Pharmaceuticals said that Galeterone and its novel analogs were found to reduce PDAC cell proliferation, cell viability, and colony formation ability using both gemcitabine-naive and gemcitabine-resistant cell lines and also acted synergistically with gemcitabine to further enhance anti-proliferative effects. Additional in vitro assays demonstrated that galeterone and its analogs reduced tumor cell migration, invasion and reduced MMP9 secretion. At a molecular level, galeterone modulated oncotargets and translational machinery, including the Mink1/2-eIF4E axis.

Tokai Pharmaceuticals is a biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally- driven diseases.

More information:

www.tokaipharma.com

((Comments on this story may be sent to newsdesk@closeupmedia.com))



(c) 2015 ProQuest Information and Learning Company; All Rights Reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Oct 23: Vitamin D Primer for Pharmacy Professionals
Oct 24: Metabolic Syndrome: The Heart of Any Wellness Practice
Oct 25: Dispensing Controlled Substances in Today’s Pharmacy
Oct 26: Management of Schizophrenia & Acute Agitation
Oct 27: Influenza 2017-2018: An Update on Prevention and Treatment
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415